Immune checkpoint inhibitors are known to produce immune-related adverse events(irAE)that require medical management. Herein, we report a case of a patient treated with pembrolizumab who experienced a Grade 3 interrupted skin disorder. The patient is a 67-year-old female diagnosed with right maxillary gingival squamous cell carcinoma(cT4aN0M0, Stage ⅣA)and underwent partial right maxillectomy, right extended supra-omohyoid neck dissection, and maxillary reconstruction using a forearm flap. Six months postoperatively, late lymph node metastases with extracapsular spread was found in the right buccal lymph node and the left neck, and the patient underwent right buccal lymphadenectomy and left modified radical neck dissection. After postoperative combined chemoradiotherapy(cisplatin plus IMRT)followed by 13 courses of cetuximab plus paclitaxel, a recurrent lesion was found in the right buccal region. After 8 courses of pembrolizumab, a skin rash appeared on the forearm, chest, and back, which was diagnosed as Grade 3 irAE, requiring hospitalization. The patient was re-instituted after waiting for improvement of the skin disorder. The pembrolizumab at 75% reduction dose was re-administrated, and the patient has been followed up so far.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Severe atopic dermatitis treated with Dupilumab in a CTLA-4-deficient patient: A case report and review of the literature.
SAGE Open Med Case Rep
January 2025
Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Atopic dermatitis is a chronic inflammatory skin disease associated with immune dysregulation, particularly overexpression of T helper 2 cytokines. Cytotoxic T lymphocyte-associated antigen 4 deficiency, a primary immune disorder, can exacerbate atopic dermatitis. Dupilumab, an IL-4 and IL-13 receptor antagonist, has demonstrated efficacy in controlling severe, recalcitrant atopic dermatitis by mitigating T helper 2-driven inflammation.
View Article and Find Full Text PDFPrecision medicine using molecular-target drugs in psoriatic arthritis.
Ther Adv Musculoskelet Dis
January 2025
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan.
Psoriatic arthritis (PsA) presents various clinical manifestations, including skin lesions, peripheral arthritis, axial involvement, enthesitis, nail involvement, dactylitis, and uveitis. In addition, it causes a high incidence of lifestyle-related diseases and an increase in cerebrovascular and cardiovascular events. As the pathology of PsA has been clarified, molecular-targeted drugs targeting tumor necrosis factor-α, interleukin (IL)-17A, IL-17A/F, IL-17 receptor, IL-12/23(p40), IL-23p19, Cytotoxic T-lymphocyte Antigen-4 (CTLA-4), Janus kinase, and phosphodiesterase-4 have been developed and are widely used in clinical practice.
View Article and Find Full Text PDFSkin and Soft Tissue Infection Complicated by Sepsis in an Immunocompromised Patient: A Rare Case Report.
Clin Case Rep
January 2025
Division of Infectious Diseases, Department of Medicine University of Miami Miller School of Medicine Miami Florida USA.
Physicians should consider non-O1, non-O139 (NOVC) in the differential diagnosis of cellulitis complicated by sepsis, especially in immunocompromised patients when potential exposure exists. Due to the pathogen's potential for severe infections and rising incidence from environmental changes, we emphasize the need for increased awareness and appropriate treatment guidelines.
View Article and Find Full Text PDFMonomicrobial Gram-Negative Necrotizing Fasciitis of the Lower Extremity.
Cureus
December 2024
Internal Medicine, Baylor Scott and White Health, Fort Worth, USA.
Unlike other skin and soft tissue infections, necrotizing fasciitis (NF) is a rare and potentially life-threatening condition. It is usually caused by polymicrobial infections or monomicrobial gram-positive organisms, mainly and . Monomicrobial gram-negative () NF is a rare form of NF, primarily reported in patients with underlying comorbidities or immunocompromised states.
View Article and Find Full Text PDFUnraveling melorheostosis: insights into clinical features, diagnosis, and treatment.
JBMR Plus
February 2025
Clinical Trials and Outcomes Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
Melorheostosis is a rare bone disease characterized by abundant bone formation with a characteristic radiographic appearance that resembles "dripping candle wax." Recent data have shown that the majority of cases are due to somatic activating mutations in bone. Melorheostosis has several clinical and radiographic presentations, which are now known to be caused by different somatic mutations such as , , , and .
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!